A Phase 4 interventional study of Ropivacaine and Saline in Rectus Sheath Block, Transversus Abdominis Plane Block and Enhanced Recovery After Surgery, sponsored by Tri-Service General Hospital (TSGH). Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Tri-Service General Hospital (TSGH) · Phase 4, Interventional, and Treatment
Among 165 studies in Colorectal Neoplasms with a site in Taiwan — 33 open to participants now, 53 under way, 11 of them phase 3. Colorectal Neoplasms · Taiwan.
Among the 165 studies in Colorectal Neoplasms with a site in Taiwan, this one is the 101st largest by planned enrollment of the 137 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 34 of the 52 other live ones, and was the 163rd registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
Browse Colorectal Neoplasms studies →33 of the 165 studies in Colorectal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
Chou-Chen Chen · Sites in Taiwan
National Taiwan University Hospital · Sites in Taiwan
AbbVie · Sites in Taiwan, United States, Belgium and 7 more countries
EMD Serono Research & Development Institute, Inc. · Sites in Taiwan, United States, Argentina and 16 more countries
Bristol-Myers Squibb · Sites in Taiwan, United States, Argentina and 22 more countries
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 39 · Phase 3 39 · Phase 4 5
First in 1999; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 90 is above the median of 76 across 4,800 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 209 across the 137 interventional studies, 260 across the 28 observational. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 165 have an industry lead sponsor. The 10 most frequent:
Tri-Service General Hospital (TSGH) is the lead sponsor of 38 studies on the registry; 12 are open to participants now.
Tri-Service General Hospital (TSGH) has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies in Colorectal Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05224518National Taiwan University Hospital Hsin-Chu BranchExercise Intervention to Improve Quality of Life in Patients With Colorectal Cancer | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Among the 165 studies in Colorectal Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to evaluate the impact of ultrasound-guided bilateral transversus abdominis plane block combined with rectus sheath block on postoperative pain and recovery after robotic colectomy under an enhanced recovery after surgery (ERAS) protocol.
Postoperative pain remains an important concern after robotic colectomy despite the implementation of enhanced recovery after surgery (ERAS) protocols. Although robotic colectomy is associated with smaller incisions and faster recovery than conventional open surgery, postoperative pain may still impair early ambulation, gastrointestinal recovery, and patient satisfaction. Multimodal analgesia strategies, including acetaminophen and nonsteroidal anti-inflammatory drugs, are commonly used in ERAS pathways to reduce opioid consumption and opioid-related adverse effects. However, postoperative pain during movement and opioid requirements remain clinically relevant issues.
Ultrasound-guided transversus abdominis plane (TAP) block has been reported to reduce postoperative pain and opioid consumption after colorectal surgery. In addition, rectus sheath block (RSB) may provide further analgesic benefit for midline abdominal incision pain. Nevertheless, the additional clinical benefit of combining TAP block and RSB in patients undergoing robotic colectomy within an established ERAS pathway has not been fully investigated.
This study aimed to evaluate the impact of ultrasound-guided bilateral TAP block combined with RSB on postoperative pain and recovery following robotic colectomy. Additionally, we investigated the influence of TAP block combined with RSB on postoperative opioid consumption, postoperative nausea and vomiting, early ambulation, gastrointestinal recovery, and length of hospital stay after robotic colectomy under ERAS management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
TAP+RS block with ropivacaine and standard analgesic care
Drug: Ropivacaine
TAP+RS block with saline and standard analgesic care
Drug: Saline
TAP+RS block using ropivacaine
TAP+RS block with saline
Visual Analogue Scale at Resting
Time frame: Postoperative 48 hours
Visual Analogue Scale at Movement
Time frame: Postoperative 48 hours
Postoperative Opioid Consumption
Time frame: Postoperative 48 hours
Postoperative Adverse Event
Time frame: From surgery until hospital discharge
Time to First Ambulation
Time frame: From surgery until hospital discharge
Time to First Flatus
Time frame: From surgery until hospital discharge
Hospital Stay
Time frame: At hospital discharge
Plan to share: No — There is no plan to share
Start is estimated for Jun 2026; primary completion for Mar 2028, 21 months later.
Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Tri-Service General Hospital (TSGH)